TET2 mutations are prevalent in a range of myeloid malignancies, including AML (~23%), MDS (~25%), MPN (~13%), and CMML (~50%), and also in lymphoid malignancies, including T cell lymphoma (~11.9%) and B cell lymphoma (~2%) [92,93,94]. Here, TET2 is linked to myeloproliferative disorder.